Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15004248 | 1.00 | MALT1 (0.57) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL16640299 | 0.99 | MALT1 (0.58) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL15004250 | 0.90 | MGLL (0.59) | MALT1MEN1KMT2APTGS2KDM1A | |
| SCHEMBL16640309 | 0.90 | PTGS2 (0.65) | MEN1KMT2APTGS2MAPTMGLL | |
| SCHEMBL16640308 | 0.88 | KDM1A (0.51) | MALT1MEN1KMT2APTGS2KDM1A | |
| SCHEMBL16640303 | 0.87 | MALT1 (0.65) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL16640300 | 0.87 | RPA1 (0.55) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL16640301 | 0.85 | MALT1 (0.67) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL16640307 | 0.85 | RPA1 (0.56) | MALT1MEN1KMT2APTGS2CHRNA7 | |
| SCHEMBL16640306 | 0.82 | PTGS2 (0.65) | PTGS2CHRNA7KDM1AMGLLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105388-A1 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF | PAICS, AADAC, TPMT | MALT1 28/4885MEN1 2710/4885KMT2A 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.